• +1 700 888 1234

  • Effingerstrasse 40 3008 Bern Switzerland

Alk+ France cancer poumon joins Lung Cancer Europe

We are very happy that Alk Ros1 France Cancer Poumon has become a member of Lung Cancer Europe (LuCE).
Alk+ France cancer poumon is a group of patients affected by lung cancer with ALK or ROS1 rearrangement, rare pathologies representing 1 to 5% of non-small cell lung cancers (NSCLC).
Their objectives are to:
➡️ Raise awareness of these rare and little-known forms of lung cancer
➡️ Support patients in their care journey and inform them about the disease
➡️Interact with healthcare professionals specializing in the field to stay informed of the best available and upcoming therapeutic options
➡️ Encourage research into the development of new treatments, synonymous with hope and quality of life
➡️ Represent ALK and ROS1 patients in professional and decision-making bodies and ensure that everyone has access to the latest therapeutic advances regardless of their geographical position in the territory
➡️ Raise funds to achieve our objectives, finance communications tools and activities for the benefit of patients.
They have approximately 300 members including:
➡️ Valerie Montagny – President
➡️ Sandrina Alliaume – Secretary
➡️ Anne Laurence Coursier and Adeline Chocarelle – International Relations Team
We take great pride in welcoming them and their members to LuCE and look forward to working with the organisation on all of our shared objectives.
Find out more about Alk+ France cancer poumon here.